www.usvindia.com Open in urlscan Pro
43.240.67.193  Public Scan

Form analysis
0 forms found in the DOM

Text Content

×

USV FORAYS INTO GERMAN MARKET WITH ACQUISITION OF JUTA PHARMA GMBH

Mumbai, March 26, 2018: USV Pvt. Ltd, enters the highly competitive German drug
market by acquiring Juta Pharma GmbH. The German company has more than 50
marketing authorisations for generics drugs.

Germany is home to Europe's largest and the world's fourth largest
pharmaceuticals market. It is a highly attractive R&D location ranked first in
Europe and second in the world, with respect to clinical trials. According to
market intelligence firm, the volume of generic drugs in Germany is expected to
reach USD 9.5 bn by end 2021.

Mrs. Leena Gandhi Tewari, Chairperson said, "This is a positive move to have a
presence in the German market and also the tender business. We are excited with
the synergies and the opportunities that come from the acquisition of Juta
Pharma GmbH. The strong work culture possessed by both the organisations will
enable business growth in Germany and the strategic pursuit in the European
market."

On the acquisition, Mr. Prashant Tewari, M.D. said, "Germany's drug market is a
highly competitive market. Acquisition of Juta Pharma GmbH enables launch of a
basket of products with greater speed and also the direct participation in the
tender market. The generic volume share is much higher in Germany compared to
many other European countries. We expect the business to grow to USD 25 million
in next five years."

"We are very pleased to have found an organisation with similar values, beliefs
and business goals. We really appreciate having joined the USV family and look
forward to leveraging the strengths of the combined organisation", said Mr.
Torben Laursen M.D., Juta Pharma GmbH.

USV is relying on US and Europe markets as key drivers of its export revenues,
having overcome the remediation hurdles for its Daman manufacturing facility.

Close
Toggle navigation
 * Home
 * About Us
   * Mission
   * Vision
   * Directors
   * Credo
   * Uniquely Positioned
   * Environment & Health
   * Awards
     * USV Award
     * Greentech Award
     * National Safety Council
   * CSR Policy
     
 * Products
   * API's
   * Biosimilars
     
     
     
     
     
     
     
     
     
     
     
   * Injectables
   * Opthalmics
   * Peptides
   * Solid Orals
   * Consumer Products
 * Services
   * Custom Peptide Synthesis
     
     
     
 * Markets
   * India
     * India Operations
       
     * Brand Building
     * Distribution
     * Alliances
   * International
 * Research & Development
   * Biosimilar Research
     * Molecular Biology
     * Fermentation
     * Bioassay/Immunoassay Lab
     * Downstream Processing
     * Analytical Development
     * Scale Up
   * Peptides
     * Peptides & Nucleotides
     * Scale Up
   * Process Chemistry
     * Process Chemistry Scale Up
   * Analytical
   * Dosage Development
     * Dosage Development
     * Dosage Development Scale Up
   * Intellectual Property
 * Manufacturing
   * APIs
   * Peptides
   * Solid-Orals
   * Sterile Fill and Finish
   * Biologics
   * EHS
   
   
 * Careers
   * Life @ USV
     
   * Drop Your Resume
     
 * Contact Us

 1. 
    
 2. 


YOUR RELIABLE
HEALTHCARE PARTNER


SIMPLIFYING HEALTHCARE

USV is No. 1 in the OAD market by Rx and by value and No. 1 in Cardiology by Rx.
We have held these positions consistently for the past 2 decades.


UNIQUELY
POSITIONED

We occupy a unique space in the pharmaceutical industry. While we compete
successfully with reputed multinationals in the Finished Dosage markets in India
and a number of Asian, African and CIS countries.

NEWS
USV has changed capsule colour of Ecosprin AV effective from July 2020 Read More
         USV Private Limited forays into German market with acquisition of Juta
Pharma GmbH Read More        USV acquires brand Jalra & Jalra-M from Novartis
for the Indian market.

We are a 58 year old leading healthcare company which began as a joint venture
with USV & P Inc. USA, a subsidiary of Revlon. Our product offering today
includes Active Pharmaceutical Ingredients (APIs), Peptides, Biosimilars,
Injectables and Ophthalmics and Solid Orals. Read More...


HEALTHCARE COMPANY INDIA

 * Solid-Orals
 * API's
 * Biosimilars
 * Injectable
 * Opthalmic
 * Peptides
 * Solid-Orals
 * API's
 * Biosimilars
 * Injectable
 * Opthalmic
 * Peptides



About Us
 * Mission
 * Vision
 * Directors
 * Credo
 * Uniquely Positioned
 * Environment Health
 * Awards
 * CSR-Policy

Products
 * API's
 * Biosimilars
 * Injectables
 * Opthalmics
 * Peptides
 * Solid Orals
 * Custom Peptide Synthesis
 * Quotation Form
 * Terms And Conditions

Markets
 * India
 * International

Research & Development
 * Biosimilar Research
 * Peptides
 * Process Chemistry
 * Analytical
 * Dosage Development
 * Intellectual Property

Manufacturing
 * APIs
 * Peptides
 * Solid Orals
 * Sterile Fill and Finish
 * Biologics

Career
 * Great Place to Work
 * Opportunities
 * Drop Your Resume
 * ASK Online Testing
 * Contact Us
 * Sitemap


© 2021 USV Private Limited. All Rights Reserved.

Website Development by Sharptech Digital Marketing Agency